MedTrace Logo

A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men

NCT07015918 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-09-10

No results posted yet for this study

Summary

The purpose of this study is to learn about how much the study medicine PF-07976016 will be taken up and processed by healthy male participants. The total number of weeks of the study is up to approximately 12 weeks.

Conditions

  • Healthy Male Volunteers

Interventions

DRUG

[14C] PF-07976016

\[14C\] PF-07976016 liquid (oral) formulation

DRUG

PF-07976016

PF-07976016 liquid (oral) formulation

DRUG

[14C] PF-07976016

\[14C\] PF-07976016 intravenous (IV) formulation

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-04
Primary Completion
2025-07-16
Completion
2025-08-14
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07015918 on ClinicalTrials.gov